XML 63 R53.htm IDEA: XBRL DOCUMENT v3.21.2
REVENUE Disaggregated Revenue Table (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Disaggregation of Revenue [Line Items]          
Accounts Receivable, Allowance for Credit Loss $ 20,900,000   $ 20,900,000   $ 22,100,000
Unbilled Services, Allowance for Credit Loss 11,400,000   11,400,000   11,300,000
Note Receivable, Allowance for Credit Loss 5,700,000   5,700,000   5,700,000
Allowance for Credit Loss $ 38,000,000.0   38,000,000.0   39,100,000
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings     (400,000)    
Allowance for Credit Loss, Write Off     700,000    
Sales Commission Amortization Period Minimum 1 year        
Deferred Revenue, Revenue Recognized     233,000,000.0 $ 102,200,000  
Contract with Customer, Asset, before Allowance for Credit Loss $ 648,400,000   648,400,000   548,100,000
Revenue, Remaining Performance Obligation, Amount $ 5,616,600,000   5,616,600,000    
Long Term Contracts Duration Minimum 1 year        
Long Term Contracts Duration Maximum 8 years        
Contract with Customer, Performance Obligation Satisfied in Previous Period $ 12,200,000 $ 4,000,000.0 28,700,000 13,700,000  
Contract with Customer, Liability 529,600,000   529,600,000   492,200,000
Capitalized Contract Cost, Amortization 3,000,000.0 2,300,000 6,500,000 5,300,000  
Accrued Sales Commission 36,400,000   36,400,000   32,600,000
Capitalized Contract Cost, Net 14,900,000   14,900,000   12,600,000
Amount of Deferred Costs Related to Long-term Contracts 51,300,000   51,300,000   45,200,000
Amortization of Deferred Sales Commissions 6,400,000 $ 5,500,000 13,300,000 $ 10,800,000  
Unbilled Contracts Receivable $ 637,000,000.0   $ 637,000,000.0   536,800,000
Percent of Revenue Contributed 100.00% 100.00% 100.00% 100.00%  
Sales Commission Amortization Period Maximum 5 years        
Revenues $ 3,840,700,000 $ 2,768,800,000 $ 8,002,200,000 $ 5,592,600,000  
Europe [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 12.00% 12.00% 11.00% 13.00%  
North America          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 84.00% 79.00% 85.00% 79.00%  
Other countries [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 4.00% 9.00% 4.00% 8.00%  
UNITED STATES          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 80.50% 76.90% 81.70% 76.80%  
Revenues $ 3,091,300,000 $ 2,129,000,000.0 $ 6,537,400,000 $ 4,294,200,000  
Medicare and Medicaid [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 6.00% 7.00% 6.00% 7.00%  
LabCorp Diagnostics [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 61.00% 61.00% 63.00% 60.00%  
Revenues $ 2,365,500,000 $ 1,692,700,000 $ 5,123,300,000 $ 3,394,700,000  
LabCorp Diagnostics [Member] | Europe [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | North America          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 61.00% 61.00% 63.00% 60.00%  
LabCorp Diagnostics [Member] | Other countries [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | Client [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 17.00% 21.00% 18.00% 19.00%  
LabCorp Diagnostics [Member] | Client [Member] | Europe [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | Client [Member] | North America          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 17.00% 21.00% 18.00% 19.00%  
LabCorp Diagnostics [Member] | Client [Member] | Other countries [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | Self-Pay [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 7.00% 7.00% 6.00% 7.00%  
LabCorp Diagnostics [Member] | Self-Pay [Member] | Europe [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | Self-Pay [Member] | North America          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 7.00% 7.00% 6.00% 7.00%  
LabCorp Diagnostics [Member] | Self-Pay [Member] | Other countries [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | Medicare and Medicaid [Member] | Europe [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | Medicare and Medicaid [Member] | North America          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 6.00% 7.00% 6.00% 7.00%  
LabCorp Diagnostics [Member] | Medicare and Medicaid [Member] | Other countries [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | Third party [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 31.00% 26.00% 33.00% 27.00%  
LabCorp Diagnostics [Member] | Third party [Member] | Europe [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
LabCorp Diagnostics [Member] | Third party [Member] | North America          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 31.00% 26.00% 33.00% 27.00%  
LabCorp Diagnostics [Member] | Third party [Member] | Other countries [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 0.00% 0.00% 0.00% 0.00%  
Covance Drug Development [Member]          
Disaggregation of Revenue [Line Items]          
Unbilled Contracts Receivable $ 1,086,200,000   $ 1,086,200,000   $ 1,001,500,000
Percent of Revenue Contributed     37.00%    
Revenues $ 1,495,200,000 $ 1,093,700,000 $ 2,933,400,000 $ 2,237,500,000  
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 39.00% 39.00% 37.00% 40.00%  
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member] | Europe [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 12.00% 12.00% 11.00% 13.00%  
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member] | North America          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 23.00% 18.00% 22.00% 19.00%  
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member] | Other countries [Member]          
Disaggregation of Revenue [Line Items]          
Percent of Revenue Contributed 4.00% 9.00% 4.00% 8.00%  
Minimum [Member]          
Disaggregation of Revenue [Line Items]          
Capitalized Contract Cost, Amortization Period 2 years   2 years    
Maximum [Member]          
Disaggregation of Revenue [Line Items]          
Capitalized Contract Cost, Amortization Period 5 years   5 years    
Notes Receivable [Member]          
Disaggregation of Revenue [Line Items]          
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings     $ 0    
Allowance for Credit Loss, Write Off     0    
Unbilled Contracts Receivable [Member]          
Disaggregation of Revenue [Line Items]          
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings     0    
Allowance for Credit Loss, Write Off     (100,000)    
Accounts Receivable [Member]          
Disaggregation of Revenue [Line Items]          
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings     (400,000)    
Allowance for Credit Loss, Write Off     $ 800,000